GenScript Biotech Releases Data Security White Paper 2024, Demonstrating Commitment to Data Security and Sustainable Development

On May 29, GenScript Biotech Corporation (HK.1548)，a world leader in technologies and services for life science R&D and manufacture, officially released its "Data Security White Paper 2024," showcasing the latest advancements and commitments in data security. The White Paper emphasizes comprehensive protection throughout the data lifecycle, aiming for lawful collection, rational use, static transparency, and dynamic control. It also reflects the company’s deepened commitment to its Environmental, Social, and Governance (ESG) strategy.

The White Paper details GenScript's extensive certifications in security compliance, including ISO9001, ISO27001, ISO13485, and etc. These certifications underscore the company's professionalism and reliability in quality management, information security, and regulatory compliance in the medical device industry. Additionally, GenScript has received certifications from the AAALAC and the OLAW, further demonstrating the company’s commitment to ethical and compliant management of animal experiments and occupational health.

The White Paper also delves into GenScript's data security governance system, covering security measures for data collection, storage, transmission, processing, backup, and recovery. This reflects the company’s strong commitment to protecting customer data, intellectual property, and privacy. To address the risks and challenges in its global strategy and operations, GenScript has established several committees, including the Risk Management and ESG Committee, Information Security Committee, Data Compliance Committee, and Biosafety Committee, which are responsible for risk identification, analysis, assessment, monitoring, and reporting, as well as the overall management of information security and biosafety.

GenScript's ESG practices are evident in both its internal management and external certifications. The company actively fulfills its social responsibilities by promoting education and scientific research in the biotechnology industry through donations and large-scale public welfare events. It also reduces its environmental impact through green production and circular economy initiatives. Sherry Shao, rotating CEO of GenScript, stated, "Data security and privacy protection are crucial parts of our commitment to stakeholders，including customers, partners, and regulators，and are core elements of our ESG strategy. Through this White Paper, we aim to showcase GenScript's efforts and achievements in data security and ESG to all stakeholders."

GenScript Group demonstrates its commitment to continuous improvement in ESG practices. Regularly engaging third-party auditors for information security management and risk assessments ensures its practices align with international standards. Additionally, GenScript joined the United Nations Global Compact (UNGC) in 2023, incorporating its ten principles into strategic planning. Notably, the company received a Bronze rating from EcoVadis, a prestigious sustainability assessment platform, ranking in the top 35% of over 130,000 companies for environmental impact and sustainable procurement.

ProBio, a subsidiary of the Group, has also released its highly anticipated "Data Security White Paper 2024." Following the Group’s unified standards and requirements, ProBio has established an information firewall to ensure data security and sustainable, positive operations. The "GenScript Biotech Corporation Data Security White Paper 2024" and the "ProBio Data Security White Paper 2024" are now publicly available for download on the company’s official website:

https://www.genscript.com.cn/genscript-information-security.html

https://www.probiocdmo.cn/information-security.html

For more information, please visit GenScript Biotech's official website https://www.genscript.com